CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis
Frontiers in Oncology · 11.08.2026 · 16
DOI: 10.3389/fonc.2026.1860307 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 11.08.2026. Verfasst von Meng-Jiao Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with limited treatment options for relapsed/refractory (R/R) cases. CAR T-cell therapy and CD20×CD3 bispecific antibodies are promising immunotherapies, but no study has systematically compared their efficacy and safety in R/R MCL.
Methods
This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines and registered in PROSPERO (CRD42024622564). A comprehensive search of PubMed, Embase, and the Cochrane Library (from inception to October 27, 2024) was performed to identify studies evaluating CAR T-cell therapy and bispecific antibodies in R/R MCL (third-line or later). Random-effects and fixed-effects models were used to calculate pooled complete response (CR) rates, overall response (OR) rates, and Grade ≥3 adverse events. Sensitivity analyses were conducted to assess the robustness of the results.
Results
Five studies (237 patients) were included. Pooled CR rates were 0.63(95% CI, 0.51-0.74)for bispecific antibodies and 0.70(95%CI, 0.63-0.77) for CAR T-cell therapy (P <0.05). OR rates were similar (0.75 vs. 0.88). Grade ≥3 cytokine release syndrome rates were comparable (0.06 vs. 0.06), but neurotoxicity cannot be compared.
Conclusion
CAR T-cell therapy demonstrated higher CR rates versus bispecific antibodies, supporting their role as effective third-line treatments for R/R MCL. Randomized trials are needed to confirm these findings. Systematic Review Registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42024622564.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China.
- Department of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan, China.
- Institute of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China.
- College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China.
- Reproductive Medicine Center, The General Hospital of Western Theater Command, Chengdu, Sichuan, China.
- Tissue Stress Injury and Functional Repair Key Laboratory of Sichuan Province, Chengdu, Sichuan, China.
Zitieren
APA
Li, M. J., Qiu, L., Chen, D., Li, C. Y., He, Y., Li, Y. L., Cen, Y. L., Ren, S. H., Yao, H., & Fan, F. Y. (2026). CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1860307
Vancouver
Li MJ, Qiu L, Chen D, Li CY, He Y, Li YL, et al. CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1860307
BibTeX
@article{Li2026,
author = {Li, Meng-Jiao and Qiu, Ling and Chen, Dan and Li, Cai-Yang and He, Ying and Li, Yan-Ling and Cen, Ya-Li and Ren, Shi-Hui and Yao, Hao and Fan, Fang-Yi},
title = {CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1860307}
}
EUVIMED